2/9
11:06 am
lly
Novo is suing Hims & Hers to halt obesity drug copycats [Los Angeles Times (CA)]
Low
Report
Novo is suing Hims & Hers to halt obesity drug copycats [Los Angeles Times (CA)]
2/9
08:04 am
lly
Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from $1,200.00 to $1,285.00. They now have a "buy" rating on the stock.
Low
Report
Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from $1,200.00 to $1,285.00. They now have a "buy" rating on the stock.
2/9
07:00 am
lly
Lilly to acquire Orna Therapeutics to advance cell therapies
Low
Report
Lilly to acquire Orna Therapeutics to advance cell therapies
2/7
09:40 am
lly
Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at Leerink Partners from $1,234.00 to $1,296.00. They now have an "outperform" rating on the stock.
Low
Report
Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at Leerink Partners from $1,234.00 to $1,296.00. They now have an "outperform" rating on the stock.
2/7
08:48 am
lly
Goldman Sachs Reaffirms Buy on Eli Lilly and Company (LLY), Citing 25% Growth Outlook [Yahoo! Finance]
Low
Report
Goldman Sachs Reaffirms Buy on Eli Lilly and Company (LLY), Citing 25% Growth Outlook [Yahoo! Finance]
2/7
06:16 am
lly
Weight-loss drugs to compete on biggest stage with Super Bowl ads [Yahoo! Finance Canada]
Low
Report
Weight-loss drugs to compete on biggest stage with Super Bowl ads [Yahoo! Finance Canada]
2/6
02:56 pm
lly
Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data [CNBC]
Low
Report
Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data [CNBC]
2/6
09:58 am
lly
Trump unveils discounted drug platform claiming to cut patient costs [MSNBC.com]
Low
Report
Trump unveils discounted drug platform claiming to cut patient costs [MSNBC.com]
2/5
05:32 pm
lly
Eli Lilly: Positives Outweigh The Concerns [Seeking Alpha]
Medium
Report
Eli Lilly: Positives Outweigh The Concerns [Seeking Alpha]
2/5
04:00 pm
lly
ELI LILLY AND COMPANY INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Eli Lilly and Company’s Directors and Officers for Breach of Fiduciary Duties – LLY
Medium
Report
ELI LILLY AND COMPANY INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Eli Lilly and Company’s Directors and Officers for Breach of Fiduciary Duties – LLY
2/5
01:29 pm
lly
Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at JPMorgan Chase & Co. from $1,150.00 to $1,300.00. They now have an "overweight" rating on the stock.
Low
Report
Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at JPMorgan Chase & Co. from $1,150.00 to $1,300.00. They now have an "overweight" rating on the stock.
2/5
01:02 pm
lly
Eli Lilly and Company (NYSE:LLY) was given a new $1,281.00 price target on by analysts at Truist Financial Corporation.
Low
Report
Eli Lilly and Company (NYSE:LLY) was given a new $1,281.00 price target on by analysts at Truist Financial Corporation.
2/5
11:03 am
lly
Eli Lilly and Company (NYSE:LLY) had its "outperform" rating reaffirmed by analysts at Scotiabank.
Low
Report
Eli Lilly and Company (NYSE:LLY) had its "outperform" rating reaffirmed by analysts at Scotiabank.
2/5
10:36 am
lly
TrumpRx set to launch, but it's unclear if it will lower drug prices for most patients [CNN]
Low
Report
TrumpRx set to launch, but it's unclear if it will lower drug prices for most patients [CNN]
2/5
10:27 am
lly
Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at Cantor Fitzgerald from $985.00 to $1,205.00. They now have an "overweight" rating on the stock.
Low
Report
Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at Cantor Fitzgerald from $985.00 to $1,205.00. They now have an "overweight" rating on the stock.
2/5
10:06 am
lly
TrumpRx set to launch, but it's unclear if it will lower drug prices for most patients [CNN]
Low
Report
TrumpRx set to launch, but it's unclear if it will lower drug prices for most patients [CNN]
2/5
10:04 am
lly
Eli Lilly and Company (NYSE:LLY) was given a new $1,260.00 price target on by analysts at The Goldman Sachs Group, Inc..
Low
Report
Eli Lilly and Company (NYSE:LLY) was given a new $1,260.00 price target on by analysts at The Goldman Sachs Group, Inc..
2/5
09:07 am
lly
Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at Morgan Stanley from $1,290.00 to $1,313.00. They now have an "overweight" rating on the stock.
Low
Report
Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at Morgan Stanley from $1,290.00 to $1,313.00. They now have an "overweight" rating on the stock.
2/5
08:44 am
lly
Eli Lilly and Company (NYSE:LLY) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
Medium
Report
Eli Lilly and Company (NYSE:LLY) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
2/5
08:11 am
lly
Eli Lilly and Company (NYSE:LLY) had its "outperform" rating reaffirmed by analysts at BMO Capital Markets.
Medium
Report
Eli Lilly and Company (NYSE:LLY) had its "outperform" rating reaffirmed by analysts at BMO Capital Markets.
2/4
08:07 pm
lly
Eli Lilly and Company (LLY) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
Eli Lilly and Company (LLY) Q4 2025 Earnings Call Transcript [Seeking Alpha]
2/4
06:48 pm
lly
Eli Lilly Stock Soars While Novo Nordisk Sinks—Why the Weight-Loss Leaders Are Headed in Opposite Directions [Yahoo! Finance]
Medium
Report
Eli Lilly Stock Soars While Novo Nordisk Sinks—Why the Weight-Loss Leaders Are Headed in Opposite Directions [Yahoo! Finance]
2/4
05:51 pm
lly
Eil Lilly shares jump on strong GLP-1 sales, as Novo Nordisk tumbles [Yahoo! Finance]
Medium
Report
Eil Lilly shares jump on strong GLP-1 sales, as Novo Nordisk tumbles [Yahoo! Finance]
2/4
02:52 pm
lly
Eli Lilly's GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026 [CNBC]
Low
Report
Eli Lilly's GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026 [CNBC]
2/4
02:47 pm
lly
We're raising our price target on Eli Lilly as the GLP-1 leader delivers a huge beat [CNBC]
Low
Report
We're raising our price target on Eli Lilly as the GLP-1 leader delivers a huge beat [CNBC]